Iowa Admin. Code r. 653-13.12 - Standards of practice-tick-borne disease diagnosis and treatment
(1)
Exemption from discipline. A person licensed by the board
under Iowa Code chapter 148 shall not be subject to discipline under this
chapter or the board's enabling statute based solely on the physician's
recommendation or provision of a treatment method for Lyme disease or other
tick-borne disease if the recommendation or provision of such treatment meets
all the following criteria:
a. The treatment
is provided after an examination is performed and informed consent is received
from the patient.
b. The physician
identifies a medical reason for recommending or providing the
treatment.
c. The treatment is
provided after the physician informs the patient about other recognized
treatment options and describes to the patient the physician's education,
experience, and credentials regarding the treatment of Lyme disease or other
tick-borne disease.
d. The
physician uses the physician's own medical judgment based on a thorough review
of all available clinical information and Lyme disease or other tick-borne
disease literature to determine the best course of treatment for the individual
patient.
e. The treatment will not,
in the opinion of the physician, result in the direct and proximate death of or
serious bodily injury to the patient.
(2)
Lyme disease treatment.
Most cases of Lyme disease can be treated successfully with a few weeks of
antibiotics. Over the past several years, the International Lyme and Associated
Diseases Society (ILADS) has supported longer courses of antibiotics for some
patients, versus the prescribed treatment durations identified by the
Infectious Diseases Society of America (IDSA) and referenced by the CDC. While
IDSA has expressed concern about overtreatment, ILADS points out that treatment
decisions should be based on a risk-benefit analysis. Both groups have
published evidence-based guidelines.
(3)
Tick-borne diseases.
According to the CDC, tick-borne diseases include:
a.
Anaplasmosis is
transmitted to humans by tick bites primarily from the blacklegged tick
(Ixodes scapularis) in the northeastern and upper midwestern
regions of the United States (U.S.) and the western blacklegged tick
(Ixodes pacificus) along the Pacific coast.
b.
Babesiosis is caused by
microscopic parasites that infect red blood cells. Most human cases of
babesiosis in the U.S. are caused by Babesia microti.
Babesia microti is transmitted by the blacklegged tick
(Ixodes scapularis) and is found primarily in the northeastern
and upper midwestern regions of the U.S.
c.
Borrelia mayonii
infection has recently been described as a cause of illness in the upper
midwestern region of the U.S. This infection has been found in blacklegged
ticks (Ixodes scapularis) in Minnesota and
Wisconsin.Borrelia mayonii is a new species and is the only
species besides B. burgdorferi known to cause Lyme disease in
North America.
d.
Borrelia
miyamotoi infection has recently been described as a cause of illness
in the U.S. This infection is transmitted by the blacklegged tick
(Ixodes scapularis) and has a geographic range similar to that
of Lyme disease.
e.
Bourbon
virus infection has been identified in a limited number of patients in
the midwestern and southern regions of the U.S. At this time, it is not known
if the virus might be found in other areas of the U.S.
f.
Colorado tick fever is
caused by a virus transmitted by the Rocky Mountain wood tick
(Dermacentor andersoni). Colorado tick fever occurs in the
Rocky Mountain states at elevations of 4,000 to 10,500 feet.
g.
Ehrlichiosis is
transmitted to humans by the lone star tick (Amblyomma
americanum), found primarily in the south central and eastern regions
of the U.S.
h.
Heartland
virus cases have been identified in the midwestern and southern
regions of the U.S. Studies suggest that lone star ticks (Amblyomma
americanum) can transmit the virus. It is unknown if the virus may be
found in other areas of the U.S.
i.
Lyme disease is transmitted by the blacklegged tick
(Ixodes scapularis) in the northeastern and upper midwestern
regions of the U.S. and by the western blacklegged tick (Ixodes
pacificus) along the Pacific coast.
j.
Powassan disease is
transmitted by the blacklegged tick (Ixodes scapularis) and
the groundhog tick (Ixodes cookei). Cases have been reported
primarily from northeastern states and the Great Lakes region.
k.
Rickettsia parkeri
rickettsiosis is transmitted to humans by the Gulf Coast tick
(Amblyomma maculatum).
l.
Rocky Mountain spotted
fever is transmitted by the American dog tick (Dermacentor
variabilis), Rocky Mountain wood tick (Dermacentor
andersoni), and the brown dog tick (Rhipicephalus
sanguineus) in the U.S. The brown dog tick and other tick species are
associated with Rocky Mountain spotted fever in Central America and South
America.
m.
Southern
tick-associated rash illness is transmitted via bites from the lone
star tick (Amblyomma americanum) found in the southeastern and
eastern regions of the U.S.
n.
Tick-borne relapsing fever is transmitted to humans through
the bite of infected soft ticks. Tick-borne relapsing fever has been reported
in 15 states: Arizona, California, Colorado, Idaho, Kansas, Montana, Nevada,
New Mexico, Ohio, Oklahoma, Oregon, Texas, Utah, Washington, and Wyoming and is
associated with sleeping in rustic cabins and vacation homes.
o.
Tularemia is transmitted
to humans by the dog tick (Dermacentor variabilis), the wood
tick (Dermacentor andersoni), and the lone star tick
(Amblyomma americanum). Tularemia occurs throughout the
U.S.
p.
364D
rickettsiosis (Rickettsia phillipi) is transmitted to
humans by the Pacific Coast tick (Dermacentor occidentalis ).
This is a new disease that has been found in California.
(4)
Grounds for discipline.
A physician may be subject to disciplinary action for violation of these rules
or the rules found in 653-Chapter 23. Grounds for discipline include but are
not limited to the following:
a. The
physician fails to perform and document an appropriate examination or fails to
obtain and document appropriate informed consent from the patient.
b. The physician fails to identify and
document a medical reason for recommending or providing the
treatment.
c. The physician fails
to inform the patient about other recognized treatment options or fails to
describe to the patient the physician's education, experience, and credentials
regarding the treatment of Lyme disease or other tick-borne diseases.
d. The physician fails to use the physician's
own medical judgment based on a thorough review of all available clinical
information and Lyme disease or other tick-borne disease literature to
determine the best course of treatment for the individual patient.
e. The treatment provided, in the opinion of
the physician, will likely result in the direct and proximate death of or
serious bodily injury to the patient.
Notes
State regulations are updated quarterly; we currently have two versions available. Below is a comparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare.
(1) Definition. For purposes of this rule :
"Authorized facility" means a facility as defined in Iowa Code section 135.185(1), a school district, or an accredited nonpublic school.
(2) Notwithstanding any other provision of law to the contrary, a physician may prescribe epinephrine auto-injectors, bronchodilator canisters, bronchodilator canisters and spacers, or opioid antagonists in the name of an authorized facility to be maintained for use pursuant to Iowa Code sections 135.185, 135.190, 280.16 and 280.16A.
(3) A physician who prescribes epinephrine auto-injectors, bronchodilator canisters, bronchodilator canisters and spacers, or opioid antagonists in the name of an authorized facility to be maintained for use pursuant to Iowa Code sections 135.185, 135.190, 280.16 and 280.16A, provided the physician has acted reasonably and in good faith, shall not be liable for any injury arising from the provision, administration, or assistance in the administration of an epinephrine auto-injector, bronchodilator canisters, bronchodilator canisters and spacers, or opioid antagonists.